Begin main content


We found 6713 result(s)

Rosuvastatin: Do we need another statin?

Last Updated: August 1, 2001
Result type: Reports

Rosuvastatin (Crestor™) is a new synthetic agent for the treatment and prevention of lipid disorders, a risk factor for coronary heart disease. Rosuvastatin is undergoing phase III clinical trials. A New Drug Application was submitted to the U.S. Food and Drug Administration in June, 2001. No information on the regulatory status in Canada is ...

A Population-based Cohort Study of Surveillance Mammography After Treatment of Primary Breast Cancer

Last Updated: July 15, 2001
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Cite as: Paszat L, Grunfeld E, van Walraven C, Coyle D, Sawka C, Yun J, McGahan L, Noorani H. A Population-based cohort Study of Surveillance Mammography After Treatment of Primary Breast Cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology report no 15. Annual surveillance mammography after t...

Oxygen carriers ”blood substitutes”

Last Updated: July 1, 2001
Result type: Reports

A number of oxygen carriers, or "blood substitutes", are undergoing clinical trials. One product (Hemopure® ) was recently licensed for use in South Africa. Another, (Hemolink™) may soon be approved for marketing in Canada. Most trials of oxygen carriers have focused on their use in surgery, primarily as a way to minimize the need ...

Inhaled Insulin for the Treatment of Diabetes Mellitus

Last Updated: June 23, 2001
Result type: Reports

Insulin delivery via inhalation, as an alternative to administration by injection, is under development. The available evidence comparing subcutaneous (sc) insulin with inhaled insulin for persons with type 1 and 2 diabetes, shows similar glycosylated hemoglobin (HgA1c) levels after three months of treatment.